Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Learn what to do in the last years before retirement to maximize your savings and prepare for a fulfilling retirement. Start planning now!
22,081 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
The Dow rose above a key threshold—49,683.30—on Thursday, putting it on a path to officially exit correction territor...
Moscow Exchange is set to publish an official XRP index as part of a broader crypto expansion that will also cover SO...
A closer look at how Lawrence Calcano built iCapital into a leading wealth-tech platform for alternatives. Learn the ...
ETF inflows rebound for crypto funds, but XRP fails to breakout as Ripple expands globally and markets digest regulat...
Investors are watching Criteo's early 2026 results to gauge the ad-tech pioneer's progress in privacy-friendly target...
Unlock the meaning behind the natr 2026 earnings transcript. Learn how to parse numbers, gauge management guidance, a...
Health fears surrounding a hantavirus danger: potential outbreak are colliding with crypto markets as meme coins link...
A standout quarterly report helped Rhythm Pharmaceuticals stock surge on Tuesday as investors embraced better-than-ex...
Bitcoin climbs to $81,000 as markets brace for weekend volatility. Pi Network’s PI token slips again, sliding to arou...
Dream Finders' unsolicited cash offer values Beazer at about $704 million, sparking a public contest as U.S. homebuil...
MercadoLibre has faced headwinds, but its long-term potential remains intact. Explore three strong reasons to conside...